Understanding the Late Effects of Surviving a Pediatric Brain Tumor (NCT03208387) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Understanding the Late Effects of Surviving a Pediatric Brain Tumor
United States42 participantsStarted 2017-06-28
Plain-language summary
The goal of this study is to learn about the cognitive and behavioral functioning of children being treated for cancer.
Who can participate
Age range
6 Years – 16 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Children Treated for Posterior Fossa Tumors:
* As per medical record or clinical report, successfully completed all medical treatment for either an M0 posterior fossa medulloblastoma without dissemination or posterior fossa low-grade astrocytoma without relapse or evidence of residual disease.
* For medulloblastoma survivors only: Previously treated with gross total resection (GTR), craniospinal irradiation with conformal posterior fossa boost radiotherapy (CSI + Boost) and chemotherapy
* For low grade astrocytoma survivors only: Previously treated with gross total resection ONLY (no chemotherapy or radiotherapy).
* As per medical record or clinician report, between 1-10 years post completion of their medical treatment for their posterior fossa brain tumor.
* Subject is between the ages of 6 through 16 years at time of consent.
* As per medical record or parent report, subject is able to tolerate an MRI without sedation.
Healthy Control Participants:
* No major medical illness, as determined by medical interview by study physician.
* As per parent report, subject is between the ages of 6 through 16 years at time of consent.
* As per parent report, subject is able to tolerate an MRI without sedation.
Exclusion Criteria:
All Participants:
* Full Scale IQ as documented to be below a standard score of \<70 based upon the study IQ assessment completed after consent.
* As per self or parent report, completed any portion of the neuropsychological battery u…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Feasibilty which is the number of eligible survivors consented per month